Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Utah Medical Products (UTMD) over the last 14 years, with Q4 2024 value amounting to $98000.0.

  • Utah Medical Products' Gains from Investment Securities rose 1666.67% to $98000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $98000.0, marking a year-over-year increase of 1666.67%. This contributed to the annual value of $98000.0 for FY2024, which is 1666.67% up from last year.
  • As of Q4 2024, Utah Medical Products' Gains from Investment Securities stood at $98000.0, which was up 1666.67% from $84000.0 recorded in Q4 2023.
  • Over the past 5 years, Utah Medical Products' Gains from Investment Securities peaked at $98000.0 during Q4 2024, and registered a low of $52000.0 during Q4 2021.
  • Over the past 5 years, Utah Medical Products' median Gains from Investment Securities value was $69000.0 (recorded in 2020), while the average stood at $74000.0.
  • As far as peak fluctuations go, Utah Medical Products' Gains from Investment Securities surged by 3269.23% in 2020, and later crashed by 2463.77% in 2021.
  • Utah Medical Products' Gains from Investment Securities (Quarter) stood at $69000.0 in 2020, then decreased by 24.64% to $52000.0 in 2021, then grew by 28.85% to $67000.0 in 2022, then grew by 25.37% to $84000.0 in 2023, then increased by 16.67% to $98000.0 in 2024.
  • Its last three reported values are $98000.0 in Q4 2024, $84000.0 for Q4 2023, and $67000.0 during Q4 2022.